vs
Ginkgo Bioworks Holdings, Inc.（DNA）与Velocity Financial, Inc.（VEL）财务数据对比。点击上方公司名可切换其他公司
Velocity Financial, Inc.的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.5倍（$51.6M vs $33.4M），Velocity Financial, Inc.同比增速更快（32.8% vs -23.8%），Velocity Financial, Inc.自由现金流更多（$17.9M vs $-47.7M），过去两年Velocity Financial, Inc.的营收复合增速更高（32.3% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
Velocity Financial, Inc.是一家总部位于美国的房地产金融企业，主要面向住宅投资物业提供专业化抵押贷款解决方案，与全美独立抵押贷款经纪人合作，为房地产投资者提供定制化的短期过桥贷款及长期租赁物业融资产品。
DNA vs VEL — 直观对比
营收规模更大
VEL
是对方的1.5倍
$33.4M
营收增速更快
VEL
高出56.7%
-23.8%
自由现金流更多
VEL
多$65.6M
$-47.7M
两年增速更快
VEL
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $51.6M |
| 净利润 | — | $34.8M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 97.0% |
| 净利率 | — | 67.3% |
| 营收同比 | -23.8% | 32.8% |
| 净利润同比 | — | 67.0% |
| 每股收益（稀释后） | $-1.41 | $0.90 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAVEL
| Q4 25 | $33.4M | $51.6M | ||
| Q3 25 | $38.8M | $49.1M | ||
| Q2 25 | $49.6M | $47.6M | ||
| Q1 25 | $48.3M | $37.5M | ||
| Q4 24 | $43.8M | $38.9M | ||
| Q3 24 | $89.0M | $35.1M | ||
| Q2 24 | $56.2M | $32.4M | ||
| Q1 24 | $37.9M | $29.5M |
净利润DNAVEL
| Q4 25 | — | $34.8M | ||
| Q3 25 | $-80.8M | $25.4M | ||
| Q2 25 | $-60.3M | $26.0M | ||
| Q1 25 | $-91.0M | $18.9M | ||
| Q4 24 | — | $20.8M | ||
| Q3 24 | $-56.4M | $15.8M | ||
| Q2 24 | $-217.2M | $14.8M | ||
| Q1 24 | $-165.9M | $17.3M |
营业利润率DNAVEL
| Q4 25 | -211.9% | 97.0% | ||
| Q3 25 | -231.8% | 72.1% | ||
| Q2 25 | -132.1% | 71.3% | ||
| Q1 25 | -184.1% | 71.7% | ||
| Q4 24 | -236.3% | 82.5% | ||
| Q3 24 | -62.0% | 60.6% | ||
| Q2 24 | -396.7% | 61.3% | ||
| Q1 24 | -469.1% | 78.8% |
净利率DNAVEL
| Q4 25 | — | 67.3% | ||
| Q3 25 | -207.9% | 51.7% | ||
| Q2 25 | -121.6% | 54.6% | ||
| Q1 25 | -188.2% | 50.4% | ||
| Q4 24 | — | 53.5% | ||
| Q3 24 | -63.3% | 45.1% | ||
| Q2 24 | -386.4% | 45.6% | ||
| Q1 24 | -437.3% | 58.5% |
每股收益（稀释后）DNAVEL
| Q4 25 | $-1.41 | $0.90 | ||
| Q3 25 | $-1.45 | $0.65 | ||
| Q2 25 | $-1.10 | $0.69 | ||
| Q1 25 | $-1.68 | $0.51 | ||
| Q4 24 | $-1.91 | $0.56 | ||
| Q3 24 | $-1.08 | $0.44 | ||
| Q2 24 | $-4.23 | $0.42 | ||
| Q1 24 | $-3.32 | $0.49 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $92.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $672.5M |
| 总资产 | $1.1B | $7.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNAVEL
| Q4 25 | $422.6M | $92.1M | ||
| Q3 25 | $495.5M | $99.0M | ||
| Q2 25 | $559.4M | $79.6M | ||
| Q1 25 | $325.3M | $51.7M | ||
| Q4 24 | $561.6M | $49.9M | ||
| Q3 24 | $616.2M | $44.1M | ||
| Q2 24 | $730.4M | $47.4M | ||
| Q1 24 | $840.4M | $34.8M |
股东权益DNAVEL
| Q4 25 | $508.6M | $672.5M | ||
| Q3 25 | $559.8M | $634.3M | ||
| Q2 25 | $613.0M | $597.9M | ||
| Q1 25 | $647.4M | $563.2M | ||
| Q4 24 | $716.1M | $516.9M | ||
| Q3 24 | $797.9M | $484.6M | ||
| Q2 24 | $833.1M | $471.3M | ||
| Q1 24 | $987.3M | $452.9M |
总资产DNAVEL
| Q4 25 | $1.1B | $7.4B | ||
| Q3 25 | $1.2B | $7.0B | ||
| Q2 25 | $1.2B | $6.5B | ||
| Q1 25 | $1.3B | $6.0B | ||
| Q4 24 | $1.4B | $5.5B | ||
| Q3 24 | $1.5B | $5.2B | ||
| Q2 24 | $1.6B | $4.9B | ||
| Q1 24 | $1.6B | $4.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $18.2M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $17.9M |
| 自由现金流率自由现金流/营收 | -142.8% | 34.6% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 0.52× |
| 过去12个月自由现金流最近4个季度 | — | $40.3M |
8季度趋势，按日历期对齐
经营现金流DNAVEL
| Q4 25 | $-47.7M | $18.2M | ||
| Q3 25 | $-31.6M | $11.5M | ||
| Q2 25 | $-40.3M | $7.7M | ||
| Q1 25 | $-51.5M | $3.5M | ||
| Q4 24 | $-42.4M | $37.8M | ||
| Q3 24 | $-103.5M | $-17.6M | ||
| Q2 24 | $-84.4M | $11.5M | ||
| Q1 24 | $-89.3M | $10.6M |
自由现金流DNAVEL
| Q4 25 | $-47.7M | $17.9M | ||
| Q3 25 | — | $11.4M | ||
| Q2 25 | $-40.3M | $7.6M | ||
| Q1 25 | $-59.1M | $3.5M | ||
| Q4 24 | $-56.1M | $37.5M | ||
| Q3 24 | $-118.6M | $-17.6M | ||
| Q2 24 | $-111.4M | $11.4M | ||
| Q1 24 | $-96.0M | $10.5M |
自由现金流率DNAVEL
| Q4 25 | -142.8% | 34.6% | ||
| Q3 25 | — | 23.2% | ||
| Q2 25 | -81.2% | 15.9% | ||
| Q1 25 | -122.4% | 9.2% | ||
| Q4 24 | -128.0% | 96.4% | ||
| Q3 24 | -133.2% | -50.3% | ||
| Q2 24 | -198.2% | 35.1% | ||
| Q1 24 | -252.9% | 35.8% |
资本支出强度DNAVEL
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 15.8% | 0.2% | ||
| Q4 24 | 31.3% | 0.7% | ||
| Q3 24 | 16.9% | 0.2% | ||
| Q2 24 | 48.1% | 0.3% | ||
| Q1 24 | 17.7% | 0.1% |
现金转化率DNAVEL
| Q4 25 | — | 0.52× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 1.81× | ||
| Q3 24 | — | -1.11× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.61× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
VEL
| Related Party | $19.3M | 37% |
| Nonrelated Party | $16.9M | 33% |
| Other | $15.4M | 30% |
